MCMaría Paula Cornejo

María Paula Cornejo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


María Paula Cornejo has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Mario Perello

    Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology [IMBICE, Argentine Research Council (CONICET) and Scientific Research Commission, Province of Buenos Aires (CIC-PBA), National University of La Plata], La Plata, Buenos Aires, Argentina; Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden

    14 shared publications
  • Pablo Nicolas De Francesco

    Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology [IMBICE, Argentine Research Council (CONICET) and Scientific Research Commission, Province of Buenos Aires (CIC-PBA), National University of La Plata], La Plata, Argentina

    11 shared publications
  • Mirta Reynaldo

    Laboratorio de Neurofisiología, Instituto Multidisciplinario de Biología Celular [IMBICE]—Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC‐PBA) y Universidad Nacional de La Plata (UNLP) Buenos Aires Argentina

    7 shared publications
  • Franco Barrile

    Laboratory of Neurophysiology, Multidisciplinary Institute of Cell Biology , La Plata, BA 1900

    5 shared publications
  • Agustina Cabral

    Laboratorio de Neurofisiología del Instituto Multidisciplinario de Biología Celular, Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina, Universidad Nacional de La Plata y Comisión de Investigaciones Científicas-Provincia de Buenos Aires, Buenos Aires, Argentina

    3 shared publications
  • Gimena Fernandez

    Laboratorio de Neurofisiología del Instituto Multidisciplinario de Biología Celular, Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina, Universidad Nacional de La Plata y Comisión de Investigaciones Científicas-Provincia de Buenos Aires, Buenos Aires, Argentina

    3 shared publications

Latest Publications

  • Open Access

    LEAP2 mediates long-term inhibition of orexigenic neurons of the hypothalamus in mice

    by Lucía Giovanini, María P. Cornejo, Ivana M. Gomez, Nahuel Wanionok, Pablo N. De Francesco, Florencia Heredia, Daniel Castrogiovanni, Leandro Urrutia, German Falasco, Sonia Cantel, et al.

    Liver-expressed antimicrobial peptide 2 (LEAP2) acts via the growth hormone secretagogue receptor (GHSR) to reduce food intake, yet the central mechanisms underlying its anorectic effects remain unclear. Here, we show that circulating LEAP2 accesses discrete brain regions, including the arcuate nucleus of the hypothalamus (ARH), where it targets orexigenic AgRP/NPY neurons. Despite the negligible local expression in the hypothalamus, LEAP2 peptide is detectable in this brain region and in the cerebrospinal fluid, suggesting peripheral origin and central retention. Using fluorescent tracers, in vivo, ex vivo, and in vitro approaches indicate that LEAP2 exhibits prolonged binding to GHSR at the plasma membrane without promoting receptor internalization, thereby limiting subsequent ghrelin action. Using male mice, we found that central or systemic LEAP2 pretreatment results in a sustained inhibition of ghrelin-induced feeding that lasts for several hours after pretreatment. Notably, LEAP2 also suppresses food intake and c-Fos induction triggered by pharmacogenetic activation of AgRP neurons, indicating a broader inhibitory control over these circuits. Together, our findings establish that LEAP2 acts as a persistent inhibitor of hypothalamic orexigenic centers, providing a mechanistic framework for its long-lasting anorectic effects. These results highlight LEAP2 as a key regulator of energy balance and support its potential as a therapeutic target for obesity and metabolic disorders.

  • Ghrelin-induced food intake in male mice requires peripheral extrahepatic GHR signaling

    by Franco Barrile, María Paula Cornejo, Pablo N De Francesco, Gabriel O de Souza, Willian O dos Santos, Frederick Wasinski, John J Kopchick, Jose Donato, Mario Perelló

    Ghrelin acts via the growth hormone secretagogue receptor (GHSR) and increases both food intake and growth hormone (GH) secretion. Studies in mice with genetic manipulations of GH receptor (GHR) revealed that GH action is required for ghrelin's orexigenic effects. However, the biological basis of this interdependence remains unclear. Here, we studied the mechanisms by which GHR contributes to ghrelin-induced hyperphagia in male mice. Transcriptomic analyses of single-cell datasets revealed that Ghr and Ghsr are co-expressed in a small subset of neurons, particularly within the hypothalamic arcuate nucleus (ARH). Systemic ghrelin administration increased food intake, circulating GH, and glycemia but did not induce GHR activation in the brain, as indicated by the absence of pSTAT5 immunoreactivity. Central GH administration failed to enhance ghrelin-induced food intake or glycemia. To evaluate the role of peripheral GHR signaling, we treated mice with the brain-impermeable GHR antagonist pegvisomant. Systemically injected pegvisomant impaired ghrelin's orexigenic effect without affecting its impact on glycemia or hypothalamic c-Fos activation, indicating that peripheral GHR signaling is required for ghrelin-induced hyperphagia. Pegvisomant did not alter refeeding-induced or AgRP neuron-mediated hyperphagia, suggesting a selective blockade of ghrelin's action. Moreover, ghrelin-induced food intake was preserved in hepatocyte-specific GHR knockout mice, despite disrupted hepatic GH signaling. Thus, peripheral, non-hepatic GHR signaling is selectively required for the orexigenic effects of ghrelin. This work reveals a critical GH-dependent, liver-independent mechanism underlying ghrelin-driven feeding, with potential implications for the neuroendocrine regulation of appetite and for therapeutic strategies targeting the ghrelin–GH axis in metabolic diseases.


  • Chronic hyperprolactinemia is associated with enhanced high‐fat diet binge eating in female mice

    by María Paula Cornejo, Felicitas Lopez‐Vicchi, Catalina de Winne, Florencia Pascual, Ana Maria Ornstein, Mirta Reynaldo, Mario Perello, Damasia Becu‐Villalobos

    Prolactin is fundamental for pregnancy and lactation, and also has numerous metabolic roles including the stimulation of appetite. Mice with chronic hyperprolactinemia display increased food intake, enhanced expression of orexigenic genes in hypothalamic brain centers, and also develop obesity. Here, we tested whether the consumption of a rewarding high‐fat diet (HFD) is altered in a mouse model of chronic hyperprolactinemia: LacDrd2KO mice, which lack dopamine Drd2 receptors in lactotrophs, preventing dopamine inhibition of prolactin secretion. We exposed control and LacDrd2KO mice to a binge‐like eating protocol in which satiated mice have access to a HFD pellet for 2‐h on four consecutive days. We found that both control and LacDrd2KO animals displayed binge‐like eating of HFD, and that hyperprolactinemic mice nearly doubled their HFD intake compared to controls. Subsequently, we analyzed the activation of mesocorticolimbic brain nuclei involved in reward processing. We observed that, in response to HFD consumption, c‐Fos levels were higher in dopaminergic neurons of the parabrachial pigmented area within the ventral tegmental area (VTA), a key brain center involved in reward regulation, and also in the core subdivision of the nucleus accumbens (Acb), the main target of dopaminergic VTA neurons. Furthermore, hyperprolactinemic mice had greater c‐Fos activation in dopaminergic neurons of the VTA in response to HFD consumption, compared to control animals. Finally, c‐Fos levels in the hypothalamic arcuate nucleus, mainly involved in the control of homeostatic food intake, were lower in LacDrd2KO mice and unaffected by HFD exposure. Current results suggest that chronic hyperprolactinemia is associated with increased consumption of a rewarding stimulus, engaging the activation of dopaminergic neurons in the VTA.


  • GHSR in a Subset of GABA Neurons Controls Food Deprivation-Induced Hyperphagia in Male Mice

    by María Paula Cornejo, Gimena Fernandez, Agustina Cabral, Franco Barrile, Florencia Heredia, Guadalupe García Romero, Juan Pablo Zubimendi Sampieri, Juan Ignacio Quelas, Sonia Cantel, Jean-Alain Fehrentz, et al.

    The growth hormone secretagogue receptor (GHSR), primarily known as the receptor for the hunger hormone ghrelin, potently controls food intake, yet the specific Ghsr-expressing cells mediating the orexigenic effects of this receptor remain incompletely characterized. Since Ghsr is expressed in gamma-aminobutyric acid-producing neurons (GABA neurons), we sought to investigate whether the selective expression of Ghsr in a subset of GABA neurons is sufficient to mediate GHSR’s effects on feeding. First, we crossed mice that express a tamoxifen-dependent Cre recombinase in the subset of GABA neurons that express glutamic acid decarboxylase 2 (Gad2) enzyme (Gad2-CreER mice) with reporter mice, and found that ghrelin mainly targets a subset of Gad2-expressing neurons located in the hypothalamic arcuate nucleus (ARH) and that is predominantly segregated from Agouti-related protein (AgRP)-expressing neurons. Analysis of various single-cell RNA sequencing datasets further corroborated that the primary subset of cells co-expressing Gad2 and Ghsr in the mouse brain are non-AgRP ARH neurons. Next, we crossed Gad2-CreER mice with reactivable GHSR-deficient mice to generate mice expressing Ghsr only in Gad2-expressing neurons (Gad2-GHSR mice). We found that ghrelin treatment induced the expression of the marker of transcriptional activation c-Fos in the ARH of Gad2-GHSR mice, yet failed to induce food intake. In contrast, food deprivation-induced refeeding was higher in Gad2-GHSR mice than in GHSR-deficient mice and similar to wild-type mice, suggesting that ghrelin-independent roles of GHSR in a subset of GABA neurons is sufficient for eliciting full compensatory hyperphagia in mice.


  • Ghrelin Action in the PVH of Male Mice: Accessibility, Neuronal Targets, and CRH Neurons Activation

    by Gimena Fernandez, Pablo N De Francesco, María P Cornejo, Agustina Cabral, Julieta P Aguggia, Victor J Duque, Nilufer Sayar, Sonia Cantel, Juan I Burgos, Jean-Alain Fehrentz, et al.

    The hormone ghrelin displays several well-characterized functions, including some with pharmaceutical interest. The receptor for ghrelin, the growth hormone secretagogue receptor (GHSR), is expressed in the hypothalamic paraventricular nucleus (PVH), a critical hub for the integration of metabolic, neuroendocrine, autonomic, and behavioral functions. Here, we performed a neuroanatomical and functional characterization of the neuronal types mediating ghrelin actions in the PVH of male mice. We found that fluorescent ghrelin mainly labels PVH neurons immunoreactive for nitric oxide synthase 1 (NOS1), which catalyze the production of nitric oxide [NO]). Centrally injected ghrelin increases c-Fos in NOS1 PVH neurons and NOS1 phosphorylation in the PVH. We also found that a high dose of systemically injected ghrelin increases the ghrelin level in the cerebrospinal fluid and in the periventricular PVH, and induces c-Fos in NOS1 PVH neurons. Such a high dose of systemically injected ghrelin activates a subset of NOS1 PVH neurons, which do not express oxytocin, via an arcuate nucleus–independent mechanism. Finally, we found that pharmacological inhibition of NO production fully abrogates ghrelin-induced increase of calcium concentration in corticotropin-releasing hormone neurons of the PVH whereas it partially impairs ghrelin-induced increase of plasma glucocorticoid levels. Thus, plasma ghrelin can directly target a subset of NO-producing neurons of the PVH that is involved in ghrelin-induced activation of the hypothalamic–pituitary–adrenal neuroendocrine axis.


  • Chlorpromazine, an Inverse Agonist of D1R-Like, Differentially Targets Voltage-Gated Calcium Channel (CaV) Subtypes in mPFC Neurons

    by Clara Inés McCarthy, Emilio Román Mustafá, María Paula Cornejo, Agustín Yaneff, Silvia Susana Rodríguez, Mario Perello, Jesica Raingo

    The dopamine receptor type 1 (D1R) and the dopamine receptor type 5 (D5R), which are often grouped as D1R-like due to their sequence and signaling similarities, exhibit high levels of constitutive activity. The molecular basis for this agonist-independent activation has been well characterized through biochemical and mutagenesis in vitro studies. In this regard, it was reported that many antipsychotic drugs act as inverse agonists of D1R-like constitutive activity. On the other hand, D1R is highly expressed in the medial prefrontal cortex (mPFC), a brain area with important functions such as working memory. Here, we studied the impact of D1R-like constitutive activity and chlorpromazine (CPZ), an antipsychotic drug and D1R-like inverse agonist, on various neuronal CaV conductances, and we explored its effect on calcium-dependent neuronal functions in the mouse medial mPFC. Using ex vivo brain slices containing the mPFC and transfected HEK293T cells, we found that CPZ reduces CaV2.2 currents by occluding D1R-like constitutive activity, in agreement with a mechanism previously reported by our lab, whereas CPZ directly inhibits CaV1 currents in a D1R-like activity independent manner. In contrast, CPZ and D1R constitutive activity did not affect CaV2.1, CaV2.3, or CaV3 currents. Finally, we found that CPZ reduces excitatory postsynaptic responses in mPFC neurons. Our results contribute to understanding CPZ molecular targets in neurons and describe a novel physiological consequence of CPZ non-canonical action as a D1R-like inverse agonist in the mouse brain.


  • Growth hormone secretagogue receptor in dopamine neurons controls appetitive and consummatory behaviors towards high-fat diet in ad-libitum fed mice

    by María Paula Cornejo, Franco Barrile, Daniela Cassano, Julieta Paola Aguggia, Guadalupe García Romero, Mirta Reynaldo, María Florencia Andreoli, Pablo Nicolás De Francesco, Mario Perello


  • Growth hormone secretagogue receptor signalling affects high‐fat intake independently of plasma levels of ghrelin andLEAP2, in a 4‐day binge eating model

    by María Paula Cornejo, Daniel Castrogiovanni, Helgi B. Schiöth, Mirta Reynaldo, Jacky Marie, Jean‐Alain Fehrentz, Mario Perello

    The growth hormone secretagogue receptor (GHSR) is a G protein‐coupled receptor that is highly expressed in the central nervous system.GHSRacts as a receptor for ghrelin and for liver‐expressed antimicrobial peptide 2 (LEAP2), which blocks ghrelin‐evoked activity.GHSRalso displays ligand‐independent activity, including a high constitutive activity that signals in the absence of ghrelin and is reduced byLEAP2.GHSRactivity modulates a variety of food intake‐related behaviours, including binge eating. Previously, we reported thatGHSR‐deficient mice daily and time‐limited exposed to a high‐fat (HF) diet display an attenuated binge‐likeHFintake compared to wild‐type mice. In the present study, we aimed to determine whether ligand‐independentGHSRactivity affects binge‐likeHFintake in a 4‐day binge‐like eating protocol. We found that plasma levels of ghrelin andLEAP2 were not modified in mice exposed to this binge‐like eating protocol. Moreover, systemic administration of ghrelin orLEAP2 did not alterHFintake in our experimental conditions. Interestingly, we found that central administration ofLEAP2 or K‐(D‐1‐Nal)‐FwLL‐NH2, which are both blockers of constitutiveGHSRactivity, reduced binge‐likeHFintake, whereas central administration of ghrelin or the ghrelin‐evokedGHSRactivity blockers [D‐Lys3]‐GHRP‐6 andJMV2959 did not modify binge‐likeHFintake. Taken together, current data indicate thatGHSRactivity in the brain affects binge‐likeHFintake in mice independently of plasma levels of ghrelin andLEAP2.


  • Open Access

    Inter-individual Variability for High Fat Diet Consumption in Inbred C57BL/6 Mice

    by Pablo N. De Francesco, María P. Cornejo, Franco Barrile, Guadalupe García Romero, Spring Valdivia, María F. Andreoli, Mario Perello

    Since inbred C57BL/6 mice are known to show inter-individual phenotypic variability for some traits, we tested the hypothesis that inbred C57BL/6 mice display a different tendency to consume a high fat (HF) diet. For this purpose, we used a compilation of HF intake data from an experimental protocol in which satiated mice were exposed to a HF pellet every morning for 2-h over 4 consecutive days. We found that mice displayed a large degree of variability in HF intake. Since day 1 HF intake significantly correlated with HF intake in successive days, we applied a hierarchical clustering algorithm on HF intake measurements in days 2, 3, and 4 in order to classify mice into “low” or “high” HF intake groups. “Low” HF intake group showed a day 1 HF intake similar to that seen in mice exposed to regular chow, while “high” HF intake group showed a higher day 1 HF intake as compared to “low” HF intake group. Both groups of mice increased HF consumption over the successive days, but “high” HF intake group always displayed a higher HF consumption than the “low” HF intake group. As compared to “low” HF intake group, “high” HF intake group showed a higher number of dopamine neurons positive for c-Fos in the VTA after the last event of HF intake. Thus, inbred C57BL/6 mice show inter-individual variability for HF intake and such feature may be linked to a different response to the rewarding properties of the HF diet.


  • Open Access

    Brain accessibility delineates the central effects of circulating ghrelin

    by Mario Perello, Agustina Cabral, María P. Cornejo, Pablo N. De Francesco, Gimena Fernandez, Maia Uriarte

    Ghrelin is a hormone produced in the gastrointestinal tract that acts via the growth hormone secretagogue receptor. In the central nervous system, ghrelin signalling is able to recruit different neuronal targets that regulate the behavioural, neuroendocrine, metabolic and autonomic effects of the hormone. Notably, several studies using radioactive or fluorescent variants of ghrelin have found that the accessibility of circulating ghrelin into the mouse brain is both strikingly low and restricted to some specific brain areas. A variety of studies addressing central effects of systemically injected ghrelin in mice have also provided indirect evidence that the accessibility of plasma ghrelin into the brain is limited. Here, we review these previous observations and discuss the putative pathways that would allow plasma ghrelin to gain access into the brain together with their physiological implications. Additionally, we discuss some potential features regarding the accessibility of plasma ghrelin into the human brain based on the observations reported by studies that investigate the consequences of ghrelin administration to humans.